GlassScriptPhysician profile
Amber N Chambers
NPI 1497720254
$1,917.46
in general payments reported to CMS, 2019-2025
25 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $212 · 2023: $449 · 2024: $619 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.33 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $537.68 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $264.69 | 2023-2024 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $215.13 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $123.58 | 2021-2024 | |
| 180 Medical, INC. | $116.02 | 2021-2023 | Cure Catheter, Gentlecath |
| Boston Scientific Corporation | $90.12 | 2024 | |
| Tolmar, INC. | $84.03 | 2023-2025 | Eligard, Jatenzo |
| Immunitybio, INC. | $62.16 | 2025 | |
| Endo Pharmaceuticals INC. | $49.41 | 2023 | Xiaflex, Aveed |
| Medtronic, INC. | $38.31 | 2022-2023 | Interstim |
| C. R. Bard, INC. & Subsidiaries | $37.31 | 2023-2025 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, Bard Urinary Drainage Bag |
| Sumitomo Pharma America, INC. | $36.90 | 2025 | Gemtesa, Orgovyx |
| Telix Pharmaceuticals | $33.90 | 2024-2025 | Illuccix |
| Organogenesis INC. | $30.11 | 2025 | Puraply Wound Matrix |
| Procept Biorobotics Corporation | $24.93 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $22.55 | 2024 | Provenge |
| Antares Pharma, INC. | $22.31 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.34 | 2025 | Lynparza |
| Smith+Nephew, INC. | $17.26 | 2024 | Stravix |
| Karl Storz Endoscopy-America | $16.23 | 2022 | |
| Pfizer INC. | $15.16 | 2023 | |
| Laborie Medical Technologies Corp. | $14.35 | 2024 | Endosheath Technology |
| Blue Earth Diagnostics | $13.73 | 2025 | Posluma |
| Allergan, INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.